NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...
Main Authors: | Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D’Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2017-03-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | http://www.drugsincontext.com/nepa-a-new-fixed-combination-of-netupitant-and-palonosetron-is-a-cost-effective-intervention-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-the-uk/ |
Similar Items
-
Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
by: Janicki PK
Published: (2016-05-01) -
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
by: Lorusso V
Published: (2016-06-01) -
Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
by: Jae Hwa Yoo, et al.
Published: (2018-12-01) -
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
by: Jianhua Chang, et al.
Published: (2020-07-01) -
Prospective randomized trial with Palonosetron verses ondensetron for postoperative nausea and vomitting in general surgical population
by: Meenal Agarwal, et al.
Published: (2016-10-01)